Moreover, anti-PD-L1 therapy promotes tryptophan catabolism as a consequence of IDO1 upregulation by IFN-γ secreted by re-invigorated tumour-infiltrating lymphocytes (82). The gene discussed is IDO1; the disease is neoplasm.